The HIF-1α Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy

Sitkovsky, 2004, Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors., Annu Rev Immunol, 22, 657, 10.1146/annurev.immunol.22.012703.104731

Caldwell, 2001, Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions, J Immunol, 167, 6140, 10.4049/jimmunol.167.11.6140

Palazon, 2012, Molecular pathways: hypoxia response in immune cells fighting or promoting cancer, Clin Cancer Res, 18, 1207, 10.1158/1078-0432.CCR-11-1591

Semenza, 2007, Life with oxygen, Science, 318, 62, 10.1126/science.1147949

Aragones, 2009, Oxygen sensors at the crossroad of metabolism, Cell Metab, 9, 11, 10.1016/j.cmet.2008.10.001

Jaakkola, 2001, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation, Science, 292, 468, 10.1126/science.1059796

Ivan, 2001, HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing, Science, 292, 464, 10.1126/science.1059817

Palazon, 2011, Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes, Cancer Res, 71, 801, 10.1158/0008-5472.CAN-10-1733

Pollok, 1993, Inducible T cell antigen 4-1BB, Analysis of expression and function. J Immunol, 150, 771

Imam, 2010, Review of positron emission tomography tracers for imaging of tumor hypoxia, Cancer Biother Radiopharm, 25, 365, 10.1089/cbr.2009.0740

Watts, 2005, TNF/TNFR family members in costimulation of T cell responses, Annu Rev Immunol, 23, 23, 10.1146/annurev.immunol.23.021704.115839

Melero, 1998, NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies, Cell Immunol, 190, 167, 10.1006/cimm.1998.1396

Choi, 2009, 4-1BB functions as a survival factor in dendritic cells, J Immunol, 182, 4107, 10.4049/jimmunol.0800459

Drenkard, 2007, CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity, FASEB J, 21, 456, 10.1096/fj.05-4739com

Tan, 1999, 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses, J Immunol, 163, 4859, 10.4049/jimmunol.163.9.4859

Kwon, 2002, Immune responses in 4-1BB (CD137)-deficient mice, J Immunol, 168, 5483, 10.4049/jimmunol.168.11.5483

Melero, 1997, Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors, Nat Med, 3, 682, 10.1038/nm0697-682

Wilcox, 2002, Cutting edge: expression of functional CD137 receptor by dendritic cells, J Immunol, 168, 4262, 10.4049/jimmunol.168.9.4262

Mittler, 2004, Anti-CD137 antibodies in the treatment of autoimmune disease and cancer, Immunol Res, 29, 197, 10.1385/IR:29:1-3:197

Melero, 2008, Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies, Trends Pharmacol Sci, 29, 383, 10.1016/j.tips.2008.05.005

McNamara, 2008, Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice, J Clin Invest, 118, 376, 10.1172/JCI33365

Yang, 2007, Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment, Cancer Res, 67, 2339, 10.1158/0008-5472.CAN-06-3593

Murillo, 2009, In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb, Eur J Immunol, 39, 2424, 10.1002/eji.200838958

Ascierto, 2010, Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies, Semin Oncol, 37, 508, 10.1053/j.seminoncol.2010.09.008

Dubrot, 2010, Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ, Cancer Immunol Immunother, 59, 1223, 10.1007/s00262-010-0846-9

Niu, 2007, Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice, J Immunol, 178, 4194, 10.4049/jimmunol.178.7.4194

Ryan, 1998, HIF-1 alpha is required for solid tumor formation and embryonic vascularization, EMBO J, 17, 3005, 10.1093/emboj/17.11.3005

Feil, 1997, Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains, Biochem Biophys Res Commun, 237, 752, 10.1006/bbrc.1997.7124

Miro-Murillo, 2011, Acute Vhl gene inactivation induces cardiac HIF-dependent erythropoietin gene expression., PLoS One, 6, e22589, 10.1371/journal.pone.0022589

Hirano, 2005, Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity, Cancer Res, 65, 1089, 10.1158/0008-5472.1089.65.3

Dong, 2002, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, 8, 793, 10.1038/nm730

Curran, 2011, Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production., PLoS One, 6, e19499, 10.1371/journal.pone.0019499

Fransen, 2011, Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody, Clin Cancer Res, 17, 2270, 10.1158/1078-0432.CCR-10-2888

Zhang, 2003, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med, 348, 203, 10.1056/NEJMoa020177

Galon, 2007, The adaptive immunologic microenvironment in colorectal cancer: a novel perspective, Cancer Res, 67, 1883, 10.1158/0008-5472.CAN-06-4806

Drake, 2006, Mechanisms of immune evasion by tumors, Adv Immunol, 90, 51, 10.1016/S0065-2776(06)90002-9

Rosenberg, 2011, Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know, Nat Rev Clin Oncol, 8, 577, 10.1038/nrclinonc.2011.116

Facciabene, 2011, Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells, Nature, 475, 226, 10.1038/nature10169

Atkuri, 2007, Importance of culturing primary lymphocytes at physiological oxygen levels, Proc Natl Acad Sci U S A, 104, 4547, 10.1073/pnas.0611732104

Atkuri, 2005, Culturing at atmospheric oxygen levels impacts lymphocyte function, Proc Natl Acad Sci U S A, 102, 3756, 10.1073/pnas.0409910102

Dang, 2011, Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1, Cell, 146, 772, 10.1016/j.cell.2011.07.033

Lukashev, 2006, Cutting edge: hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes, J Immunol, 177, 4962, 10.4049/jimmunol.177.8.4962

Ortiz-Barahona, 2010, Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction, Nucleic Acids Res, 38, 2332, 10.1093/nar/gkp1205

Taylor, 2008, Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation, J Physiol, 586, 4055, 10.1113/jphysiol.2008.157669

Sakuishi, 2011, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, J Exp Med, 207, 2187, 10.1084/jem.20100643

Wang, 2011, Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways, Curr Top Microbiol Immunol, 344, 245

Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J Clin Oncol, 28, 3167, 10.1200/JCO.2009.26.7609

So, 2008, Immune regulation and control of regulatory T cells by OX40 and 4-1BB, Cytokine Growth Factor Rev, 19, 253, 10.1016/j.cytogfr.2008.04.003

Dubrot, 2011, Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy, Int J Cancer, 128, 105, 10.1002/ijc.25333

Vezys, 2011, 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection, J Immunol, 187, 1634, 10.4049/jimmunol.1100077

Alizadeh, 2011, Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment, Blood, 118, 1350, 10.1182/blood-2011-03-345272

Boggio, 1998, Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice, J Exp Med, 188, 589, 10.1084/jem.188.3.589

Tirapu, 2004, Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens, Int J Cancer, 110, 51, 10.1002/ijc.20093